Trial Profile

A Phase 3 Open-Label Randomized Study of Quizartinib Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quizartinib (Primary) ; Cytarabine; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin; Mitoxantrone
Indications Acute myeloid leukaemia
Focus Registrational; Therapeutic Use
Acronyms QUANTUM-R
Sponsors Ambit Biosciences Corporation; Daiichi Sankyo Inc

02 Feb 2021 Status changed from active, no longer recruiting to completed.
12 Dec 2020 This trial has been completed in Czech Republic (Global End Date: 08 Sep), according to European Clinical Trials Database record.
08 Dec 2020 This trial has been completed in Hungary and Croatia as per European Clinical Trials Database record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com